ASPIRIN does not improve survival for patients admitted to hospital with Covid, a study has found.
Patients with Covid-19 are at increased risk of blood clots forming in their blood vessels.
Between November 2020 and March 2021, the Recovery trial included nearly 15,000 patients admitted to hospital with the virus an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. A total of 7351 patients were randomised to receive 150 mg of aspirin once daily and compared with 7541 patients randomised to usual care alone.
The study found no evidence that the drug treatment reduced mortality, but it did find that patients allocated to aspirin had a slightly shorter hospital stay – eight days versus nine days – and a higher proportion were discharged from hospital alive within 28 days (75% vs 74%).
For every 1000 patients treated with aspirin, approximately six more patients experienced a major bleeding event and approximately six fewer experienced clotting, researchers said. Martin Landray, from the University of Oxford, said: “This is why large randomised trials are so important – to establish which treatments work.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here